Management of disease- and treatment-related complications in patients with multiple myeloma

By Gay Francesca   Palumbo Antonio  

Medical Oncology, Vol. 27, Iss. 1, 2010-06 ,pp. : 43-52

Humana Press, Inc

Access to resources Recommend Favorite

Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma

By Wong Doo Nicole  

Leukemia and Lymphoma, Vol. 54, Iss. 7, 2013-07 ,pp. : 1465-1472

Informa Healthcare

Access to resources Recommend Favorite

Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease

By Hungria Vania   Latrilha Maria   Rodrigues Debora   Bydlowski Sergio   Chiattone Carlos   Maranhão Raul  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 1, 2004-01 ,pp. : 51-60

Springer Publishing Company

Access to resources Recommend Favorite

Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment

By Sonneveld P.   Segeren C.M.  

European Journal of Cancer, Vol. 39, Iss. 1, 2003-01 ,pp. : 9-18

Elsevier

Access to resources Recommend Favorite

Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients

By                            

Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. : 3228-3232

Spandidos Publications

Access to resources Recommend Favorite